33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Reducing Human-Tsetse Contact Significantly Enhances the Efficacy of Sleeping Sickness Active Screening Campaigns: A Promising Result in the Context of Elimination

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Control of gambiense sleeping sickness, a neglected tropical disease targeted for elimination by 2020, relies mainly on mass screening of populations at risk and treatment of cases. This strategy is however challenged by the existence of undetected reservoirs of parasites that contribute to the maintenance of transmission. In this study, performed in the Boffa disease focus of Guinea, we evaluated the value of adding vector control to medical surveys and measured its impact on disease burden.

          Methods

          The focus was divided into two parts (screen and treat in the western part; screen and treat plus vector control in the eastern part) separated by the Rio Pongo river. Population census and baseline entomological data were collected from the entire focus at the beginning of the study and insecticide impregnated targets were deployed on the eastern bank only. Medical surveys were performed in both areas in 2012 and 2013.

          Findings

          In the vector control area, there was an 80% decrease in tsetse density, resulting in a significant decrease of human tsetse contacts, and a decrease of disease prevalence (from 0.3% to 0.1%; p=0.01), and an almost nil incidence of new infections (<0.1%). In contrast, incidence was 10 times higher in the area without vector control (>1%, p<0.0001) with a disease prevalence increasing slightly (from 0.5 to 0.7%, p=0.34).

          Interpretation

          Combining medical and vector control was decisive in reducing T. b. gambiense transmission and in speeding up progress towards elimination. Similar strategies could be applied in other foci.

          Author Summary

          Sleeping sickness is a serious neglected tropical disease which has been targeted for elimination by 2020. Currently, control relies on mass screening populations at risk and treatment of cases. This strategy is compromised because it is often impossible to reach more than 75% of the population. An alternate method is to kill the tsetse fly which transmits the parasite causing the disease. To determine the value of adding vector control to medical interventions we undertook a vector control programme alongside a screen and treat programme in the Boffa disease focus of Guinea. We divided the focus into two parts (screen and treat in the western part; screen and treat plus vector control in the eastern part). In the vector control area, there was an 80% decrease in tsetse density and a decrease of disease prevalence from three cases per thousand to one case per thousand with almost no new cases being contracted during the control period. In contrast, incidence was 10 times higher in the area without vector control. Combining medical and vector control was decisive in reducing sleeping sickness transmission and could speed up the elimination process. Similar strategies could be applied in other foci.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: not found
          • Article: not found

          A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense.

            Twelve T.b. gambiense clone populations of distinct Variable Antigen Type (VAT) were combined in immune lysis tests with 340 sera of trypanosome infected patients from 8 different African countries and 267 non trypanosomiasis control sera. The diagnostic specificity of the test was 100%. At a serum dilution of 1:4 the overall test sensitivity with single VATs varied from 39.1 to 98.2% and from 12.1 to 86.8% at 1:32. At a serum dilution of 1:32 some combination tests with 2 VATs still scored above 96%. The VAT recognition patterns were clearly correlated with the geographical origin of the sera, reflecting a diversity in variable antigen repertoires.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.

              Despite the fact that eflornithine was considered as the safer drug to treat human African trypanosomiasis (HAT) and has been freely available since 2001, the difficulties in logistics and cost burden associated with this drug meant that the toxic melarsoprol remained the drug of choice. The World Health Organization responded to the situation by designing a medical kit containing all the materials needed to use eflornithine, and by implementing a training and drugs distribution programme which has allowed a transition to this much safer treatment. The introduction of the combination of nifurtimox and eflornithine (NECT) has accelerated the shift from melarsoprol to the best treatment available, due to reduced dosage and treatment time for eflornithine that has significantly lessened the cost and improved the burden of logistics encountered during treatment and distribution. The decrease in the use of more dangerous but cheaper melarsoprol has meant a rise in the per patient cost of treating HAT. Although NECT is cheaper than eflornithine monotherapy, an unexpected consequence has been a continuing rise in the per patient cost of treating HAT. The ethical decision of shifting to the best available treatment imposes a financial burden on HAT control programmes that might render long-term application unsustainable. These factors call for continuing research to provide new safer and more effective drugs that are simple to administer and cheaper when compared to current drugs.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Negl Trop Dis
                PLoS Negl Trop Dis
                plos
                plosntds
                PLoS Neglected Tropical Diseases
                Public Library of Science (San Francisco, CA USA )
                1935-2727
                1935-2735
                12 August 2015
                August 2015
                : 9
                : 8
                : e0003727
                Affiliations
                [1 ]IRD, UMR 177 IRD-CIRAD INTERTRYP, CIRDES 01 BP 454, Bobo-Dioulasso, Burkina Faso
                [2 ]PNLTHA, Ministère de la Santé, Conakry, Republique de Guinee
                [3 ]CIRDES URBIO, 01 BP 454, Bobo-Dioulasso, Burkina Faso
                [4 ]Centre MURAZ, Bobo-Dioulasso, Burkina Faso
                [5 ]Liverpool School of Tropical Medicine, Liverpool, United Kingdom
                [6 ]IRD, UMR 177 IRD-CIRAD INTERTRYP, PNLTHA-Ministère de la Santé, Conakry, Republique de Guinee
                Yale School of Public Health, UNITED STATES
                Author notes

                The authors have declared that no competing interests exist.

                Conceived and designed the experiments: FC MC JBR MJL SJT PS VJ BB. Performed the experiments: FC MC JBR MK ED OC IST JR MP MBS ML VJ BB. Analyzed the data: FC MC JBR PS VJ BB. Wrote the paper: FC MC JBR MJL SJT PS VJ BB.

                Article
                PNTD-D-14-02172
                10.1371/journal.pntd.0003727
                4534387
                26267667
                3788c2f7-daef-47b0-a41f-142d3cb67a93
                Copyright @ 2015

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

                History
                : 15 December 2014
                : 30 March 2015
                Page count
                Figures: 4, Tables: 3, Pages: 12
                Funding
                The work was supported by the Bill and Melinda Gates Foundation (grant number 1017770) and by the World Health Organisation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Custom metadata
                All relevant data are within the paper and its Supporting Information files.

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article